You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
沃華醫藥(002107.SZ):一季度淨利預增170%-230%
格隆匯 03-17 17:21

格隆匯3月17日丨沃華醫藥(002107.SZ)披露2020年第一季度業績預告,公司預計2020年1-3月實現歸屬於上市公司股東的淨利潤3654.48萬元-4466.58萬元,同比增長170%-230%。報告期內公司業績較上年同期大幅增長的主要原因:

首先,疫情期間,公司充分發揮多年積累的獨家產品的競爭優勢,迅速抓住國家醫保局關於慢性病醫保藥品“長處方”的政策機遇,全力推動治療慢性病的沃華®心可舒片、骨疏康膠囊/顆粒、荷丹片/膠囊、腦血疏口服液四大獨家支柱產品的銷售,使一季度銷售收入取得較快增長。

其次,公司目前在產的國家疫情推薦藥物及清熱解毒類藥品主要為防風通聖丸、橘紅梨膏、鳶都感冒顆粒、抗病毒口服液、小兒退熱顆粒、參苓白朮丸、複方西羚解毒片、通宣理肺丸、炎熱清顆粒、銀黃顆粒等,公司在做好防護的前提下組織加班加點生產此類藥品,為一季度銷售收入貢獻了新的增長點。

最後,公司繼續深入推進精細化管理,疫情期間加快推進數字化轉型,廣泛應用線上推廣等營銷手段,加速整合線上線下資源,顯著降低了營銷費用。採購、生產、財務及人力資源等方面的數字化轉型也同步推進,提升了管理效率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account